Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H23NO3 |
Molecular Weight | 325.4015 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=CC(=C1)[C@H]2CCCN(C[C@H]3COC4=CC=CC=C4O3)C2
InChI
InChIKey=FOESNAGBEJURCI-WMZOPIPTSA-N
InChI=1S/C20H23NO3/c22-17-7-3-5-15(11-17)16-6-4-10-21(12-16)13-18-14-23-19-8-1-2-9-20(19)24-18/h1-3,5,7-9,11,16,18,22H,4,6,10,12-14H2/t16-,18-/m0/s1
DescriptionSources: http://adisinsight.springer.com/drugs/800022078https://www.ncbi.nlm.nih.gov/pubmed/29067315 | https://www.ncbi.nlm.nih.gov/pubmed/24489014 | https://adisinsight.springer.com/drugs/800029247Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16317384 | https://www.ncbi.nlm.nih.gov/pubmed/17902637
Sources: http://adisinsight.springer.com/drugs/800022078https://www.ncbi.nlm.nih.gov/pubmed/29067315 | https://www.ncbi.nlm.nih.gov/pubmed/24489014 | https://adisinsight.springer.com/drugs/800029247
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16317384 | https://www.ncbi.nlm.nih.gov/pubmed/17902637
Juvantia Pharma and Orion developed ORM-12741, also known as ORM-10921, a novel selective antagonist of alpha-2C adrenoceptors for the treatment of depression and Alzheimer's disease. ORM-12741 participated in phase II clinical trial where was evaluated the safety and efficacy of the drug in patients with Alzheimer's disease. In spite of the successfully completed phase II, further study of the drug for this disease was discontinued. In addition, ORM-12741 participated in clinical trial phase II to prove the concept that this drug could prevent blood vessel spasms for Raynaud's phenomenon. Raynaud's phenomenon is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. However, this study was terminated because of the recommendation by study Data and Safety Monitoring Committee to the sponsor following the interim analysis of 8 subjects.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17902637 |
|||
Target ID: CHEMBL2094258 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17902637 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthritis. | 2007 Nov 1 |
|
Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. | 2017 Jan |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000184092
Created by
admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
|
PRIMARY | |||
|
DB12057
Created by
admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
|
PRIMARY | |||
|
1106938-11-7
Created by
admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
25175001
Created by
admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
|
PRIMARY | |||
|
D26C95A960
Created by
admin on Sat Dec 16 10:35:02 GMT 2023 , Edited by admin on Sat Dec 16 10:35:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY